Objective. Guidelines exist for the use of low-dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit considerations may differ in RA. While RA confers an increased CV risk, such patients more likely use NSAIDs and corticosteroids.
Introduction
Low-dose aspirin has proven benefits for secondary cardiovascular (CV) prevention and in selected populations for primary prevention [1] . Recommendations advise low-dose aspirin therapy for men aged 4579 and for women 5579 with at least a 10% 10-year risk of a CV event [1] . This calculation takes into account the increased bleeding risk associated with lowdose aspirin [2, 3] . Clinicians might consider individuals judged to have an increased risk for CV disease to be appropriate candidates for low-dose aspirin for primary prevention. Yet, this assumption may not apply to populations, such as those with RA, with other risk factors for bleeding. Indeed, low-dose ASA treatment confers little or no demonstrable benefit to patients with diabetes or peripheral arterial disease who have not had a prior CV event [4, 5] .
Patients with RA experience a 50100% increase in the risk of CV events compared with age-and gendermatched controls [6, 7] . Before the advent of modern DMARDs, rheumatic disease treatment commonly used high-dose aspirin. These two factors lead many providers to assume that low-dose aspirin would provide benefit to the majority of older adults with RA. But the frequent use of chronic NSAIDs and corticosteroids by these patients may increase the risk of gastrointestinal and renal complications from low-dose aspirin. The risk-benefit profile of low-dose aspirin in RA remains unknown.
While a randomized controlled clinical trial (RCT) would provide the best estimate of the potential risks and benefits of low-dose aspirin for primary prevention in RA, the prospect of such a trial is unlikely. An adequately powered trial would likely require over 10 000 patients with RA, which exceeds by far almost all trials in this population to date. Thus, an observational study with appropriate accounting for potential confounders in the context of a RCT could provide useful information regarding low-dose aspirin's effects on CV events. One prior study using propensity score matched cohorts found no reduction in CV events among patients with RA taking low-dose aspirin [8] . This carefully conducted study had several drawbacks, including lacking assessment of RA disease severity and no inclusion of gastrointestinal or renal outcomes.
We studied the effects of low-dose aspirin using data from patients with RA enrolled in the Prospective Randomized Evaluation of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION) trial.
Methods

Study design
The PRECISION trial was a multi-national RCT designed to test the safety of celecoxib compared with naproxen and ibuprofen. Previous publications include detailed methods for PRECISION [9, 10] . Eligible patients were those 5 18 years of age with a clinical diagnosis of OA or RA for at least 6 months who required chronic daily NSAID therapy. All patients gave written informed consent and all protocols received approval from the appropriate institutional review boards; this secondary analysis required no further approval or consent.
From the PRECISION trial population, we selected patients with RA who did not have a known prior CV event. The NSAID treatment arms were double blinded. Randomization was stratified by geographic region, lowdose aspirin use (yes or no) and arthritis type (OA or RA) and implemented using an interactive voice response system to ensure masking of allocation. All enrolled patients were provided open-label esomeprazole at 2040 mg per day. The clinical trials registration number for the PRECISION trial is NCT00346216.
Outcomes
The current analyses report findings for a composite outcome, all components of which were centrally adjudicated in a blinded fashion. The primary outcome was a composite of major NSAID toxicities, comprised of major adverse CV event (MACE) (which includes nonfatal myocardial infarction, non-fatal stroke, CV death, revascularization or hospitalization for transient ischaemic attack or unstable angina), plus clinically significant gastrointestinal, renal and all-cause mortality events.
Clinically significant gastrointestinal events included gastroduodenal haemorrhage; gastric outlet obstruction; perforation of the gastroduodenum, small bowel or large bowel; haemorrhage of the large bowel, small bowel or acute gastrointestinal haemorrhage of unknown origin; or symptomatic gastric or duodenal ulcer. Clinically significant renal events included renal insufficiency or renal failure, defined based on development of any of the following: serum creatinine 52.0 mg/dl and increase of 50.7 mg/dl from baseline; hospitalization for acute renal failure with a doubling of the baseline serum creatinine or hyperkalaemia with 550% elevation in serum creatinine; or initiation of dialysis. A Clinical Events Committee blindly adjudicated all the above endpoints utilizing pre-specified definitions.
Low-dose aspirin exposure
Patients in the PRECISION trial were allowed to use lowdose aspirin, defined as 4325 mg/day. This usage was reported at baseline and all subsequent study visits. A small percentage of patients started or stopped lowdose aspirin after the start of follow-up. The primary analyses considered baseline status, and a sensitivity analysis updated low-dose aspirin use.
Covariates
Patient characteristics were considered potential confounders and examined at baseline. These included age, gender, BMI, diabetes, hypertension, the diagnosis of dyslipidaemia, tobacco use, statin use, DMARD use, corticosteroid use and functional status (as measured by the HAQ) [11] . We also tested measured systolic and diastolic blood pressure, lipid parameters, glycated haemoglobin and serum creatinine.
Statistical analyses
The current analyses focus on a composite safety outcome, major NSAID toxicity, and compare low-dose aspirin users to non-users. This analysis focused on the intention-to-treat population through 30 months after randomization. Standardized mean differences were calculated for continuous and categorical baseline variables [12] .
Hazard ratios (HRs) and corresponding 95% CIs comparing low-dose aspirin users vs non-users for the safety outcomes of interest were calculated using Cox proportional hazards models, adjusted for age and gender. Further adjustment for other baseline variables having standardized mean difference absolute values >0.1 did not materially affect these estimates. The assumptions of proportional hazards were not violated [13] . A sensitivity analysis used time-dependent covariates to model changes is aspirin use at each visit. All analyses were performed using the SAS system (version 9.4, Cary, NC, USA).
Results
We selected patients from the PRECISION trial with RA and no known prior CV events (see supplementary Fig.  S1 , available at Rheumatology online). From the 1852 eligible subjects, 540 (29%) reported use of low-dose aspirin at baseline and 1312 (71%) no use. The aspirin users and non-users' baseline characteristics are reported in Table 1 . Aspirin users were slightly older (62.5 years vs 58.9), more likely to be male (26% vs 21%) and had higher body mass index (31.7 kg/m 2 vs 30.7). They also were more likely to have diabetes (38% vs 32%), hypertension (81% vs 74%) and dyslipidaemia (62% vs 53%). In addition, low-dose aspirin users were more likely to also use a statin lipid-lowering medication (52% vs 34%) but less likely to use a DMARD (52% vs 59%). Corticosteroid use was very similar across both groups. All three of the randomized NSAID treatment arms were well balanced across aspirin users and non-users. The frequency of major NSAID toxicity was similar across patients who used low-dose aspirin (n = 37, 6.9%) and those that did not (n = 79, 6.0%) (P = 0.50). While the components of the composite outcome were not frequent, there was no reduction in MACE between patients using low-dose aspirin (n = 22, 4.1%) and those that did not (n = 37, 2.8%) (P = 0.16), despite the higher prevalence of coronary risk factors in the ASA users. There was also no increase in renal or gastrointestinal events in the low-dose aspirin users (see Table 2 ). NSAID toxicity showed similar incidence rates for major events across low-dose aspirin users (3.30/100 patient-years) and non-users (2.94/100 patient-years) (see Table 2 ). The HAQ disability index is based on 20 questions in 8 categories regarding daily functioning; overall scores range from 0 to 3, with 0 indicating no disability and 3 indicating complete disability.
Age-and gender-adjusted models demonstrated similar risk for major NSAID toxicity (HR = 0.95, 95% CI: 0.64, 1.40) as well as for MACE (HR = 1.23, 95% CI: 0.72, 2.10) (see Table 2 ). Fully adjusted Cox regression models demonstrated similar risk between low-dose aspirin users and non-users (HR = 1.08, 95% CI: 0.69, 1.69).
Several sets of sensitivity analyses were pursued. In age-and gender-adjusted models that examined the risk of MACE or other components of the primary outcome, they showed no significant differences (see Table 2 ). Analyses using a propensity score also showed no significant differences. Finally, Cox regression models that censored subjects when aspirin status changed also yielded very similar results (see supplementary Tables S1  and S2 , available at Rheumatology online).
Discussion
Preventing CV events represents a major goal for improving health outcomes for patients with RA. Because of the heightened CV risk and known benefits of aspirin in CV prevention, low-dose aspirin seems like an attractive option in RA patients. Yet, low-dose aspirin has a relatively narrow risk-benefit ratio in the general population [14] , and the risk-benefit ratio in RA is uncertain. Using data collected as part of a large RCT comparing the safety of naproxen, ibuprofen and celecoxib, we compared outcomes among patients taking low-dose aspirin or not. We found no benefit of low-dose aspirin across a composite outcome including major CV events, clinical significant gastrointestinal events, renal insufficiency and mortality.
While these analyses have limitations, they highlight several important issues. RCTs are often not performed among subgroups of patients who have potentially important comorbidities, such as patients with RA who have increased CV risk or use medications that might change the risk-benefit ratio of interventions [14] . The analysis of relevant subgroups of patients in such trials can inform clinical practice. Patients with RA may have CV disease that reflects different mechanisms and behaves differently clinically than the general population [15] . These patients also frequently use NSAIDs and corticosteroids, which may alter the risk-benefit ratio of lowdose aspirin. Hence, clinicians should not assume that RA patients will benefit from low-dose aspirin for prevention.
The PRECISION trial provided a suitable setting to study the impact of low dose aspirin for CV prevention in RA patients. The RCT provided well-ascertained variables, including comorbidities, exposures, disease severity and blindly adjudicated outcomes. NSAID use is often not well characterized but is common in RA and impacts outcomes relevant to low-dose aspirin use, such as CV events, gastrointestinal events, renal insufficiency and mortality. The same is true for functional status, which is often limited in rheumatoid arthritis and affects the risk of outcomes. The outcomes adjudicated in the PRECISION trial were broad and included not just CV events, allowing a more complete view of risks and benefits of low-dose aspirin for prevention.
One prior study of this topic examined the risk of myocardial infarction among groups of patients with RA found in The Health Improvement Network database [8] . These investigators conducted a propensity score matched analysis and found no reduction in endpoints associated with low-dose aspirin use. The prior study did not include adjudicated outcomes, and only considered myocardial infarction. In addition, it may not have adequately excluded patients with prior CV events, but the two analyses give similar results. Both analyses call into question the value of low-dose aspirin for primary CV prevention in RA. These results conform with the results of studies of other high risk primary prevention populations such as those with diabetes or with peripheral artery disease [4, 5] .
Several reasons may explain the lack of perceived CV benefit in these two observational analyses. The cohorts were relatively small and thus the wide confidence intervals could conceal a benefit. Both studies were observational and confounding by indication, that is, more at-risk patients received low-dose aspirin, which may have biased the results against finding a benefit. Either the mix of typical medications or the nature of the CV disease negates the potential benefit. Neither study can adequately explain the null result, except if the relatively small number of outcomes produced false-negative results (type II error) in both studies. We acknowledge that the current set of analyses had limited power to detect a benefit in CV outcomes with low-dose aspirin; post hoc power calculations suggest a power of <50% to detect a 25% improvement in outcomes using low-dose aspirin. It is also possible that the use of non-selective NSAIDs may have abrogated the potential benefits of low-dose aspirin [16] .
In conclusion, the available data do not show a significant benefit nor risk in patients with RA who use low-dose aspirin for primary CV prevention. While this result may seem counter-intuitive, treatment effects of many interventions are not consistent across subgroups of patients [17] . An RCT would provide more definitive results, but consistent data from robust observational studies can guide clinical care while awaiting such a trial.
